Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES

Gene Therapy

Volumn 13, Issue 18, 2006, Pages 1351-1359

  Jia, Y ^a,b   Li, H ^a,b   Chen, W ^a,b   Li, M ^a   Lv, M ^a,b   Feng, P ^a   Hu, H ^a   Zhang, L ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; FREUND ADJUVANT; IMMUNOTOXIN; IMMUNOTOXIN DT390; LIPOSOME; MYELIN BASIC PROTEIN; PHOSPHATE BUFFERED SALINE; PLASMID DNA; RANTES; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ACTIVITY; EMULSION; EUKARYOTE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION;

3T3 CELLS; ANIMALS; CHEMOKINE CCL5; CHEMOTAXIS, LEUKOCYTE; DNA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; IMMUNOTOXINS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MUSCLE, SKELETAL; MYELIN BASIC PROTEINS; RANTES; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSFECTION;

EUKARYOTA; MURINAE;

EID: 33748323288     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302799     Document Type: Article

References (37)

1. Petry KG, Boullerne AI, Pousset F, Brochet B, Caille JM, Dousset V. Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis [J]. Pathol Biol (Paris) 2000; 48: 47-53.
2. Stinissen P, Raus J, Zhang J. Autoimmune pathogenesis of multiple sclerosis: Role of autoreactive T lymphocytes and new immunotherapeutic strategies [J]. Crit Rev Immunol 1997; 17: 33-75.
3. Xu B, Scott DW. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol 2004; 111: 47-52.
4. Namer IJ, Steibel J, Klinguer C, Trifilieff E, Mohr M, Poulet P. Magnetic resonance imaging of PLP-induced experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1998; 92: 22-28.
5. Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. J Neurol 2002; 249: 576-583.
6. Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 3866-3877.
7. Emingil G, Atilla G, Huseyinov A. Gingival crevicular fluid monocyte chemoattractant protein-1 and RANTES levels in patients with generalized aggressive periodontitis. J Clin Periodontol 2004; 31: 829-834.
8. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988; 141: 1018-1025.
9. Li Z, Yu T, Zhao P, Ma J. Immunotoxins and cancer therapy. Cell Mol Immunol 2005; 2: 106-112.
10. Cui JX, Ji JF, Lv AG, Wu WF. Construction and expression of novel immunotoxin cpIL-4(13D)-PE38KDEL with increased activity. Biochemistry (Moscow) 2005; 70: 62-68.
11. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1: 298-302.
12. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ et al. Efficacy of anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241-247.
13. Baker D, Hankey DJ. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Therapy 2003; 10: 844-853.
14. Furlan R, Pluchino S, Martino G. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 2003; 16: 385-392.
15. Weiner LP, Louie KA, Atalla LR, Kochounian HH, Du J, Wei W et al. Gene therapy in a murine model for clinical application to multiple sclerosis. Ann Neurol 2004; 55: 390-399.
16. Fife BT, Paniagua MC, Lukacs NW, Kunkel SL, Karpus WJ. Selective CC chemokine receptor expression by central nervous system-infiltrating encephalitogenic T cells during experimental autoimmune encephalomyelitis. J Neurosci Res 2001; 66: 705-714.
17. Diedrichs-Mohring M, Nelson PJ, Proudfoot AE, Thurau SR, Wildner G. The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance. J Neuroimmunol 2005; 164: 22-30.
18. Panzer U, Reinking RR, Steinmetz OM, Zahner G, Sudbeck U, Fehr S et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004; 78: 1341-1350.
19. Schroppel B, Zhang N, Chen P, Zang W, Chen D, Hudkins KL et al. Differential expression of chemokines and chemokine receptors in murine islet allografts: The role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol 2004; 15: 1853-1861.
20. Chao K, He D, Yang H, Zhang Z, Lin Q, Guo AG et al. Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004; 20: 568-571.
21. Zhang J, Liu YF, Yang SJ, Qiao Q, Cheng H, Zhang CS et al. Primary targeting of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha against hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1872-1875.
22. Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 1998; 58: 4146-4154.
23. Yoshioka Y, Tsutsumi Y, Nakagawa S, Mayumi T. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr Vasc Pharmacol 2004; 2: 259-270.
24. Tremblay CL, Giguel F, Guan Y, Chou TC, Takashima K, Hirsch MS. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother 2005; 49: 3483-3485.
25. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004; 10: 2041-2062.
26. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77: 5201-5208.
27. Koning FA, Koevoets C, van der Vorst TJ, Schuitemaker H. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther 2005; 10: 231-237.
28. Misu T, Onodera H, Fujihara K, Matsushima K, Yoshie O, Okita N et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: Imbalance of Th1/ Th2-associated chemokine signaling. J Neuroimmunol 2001; 114: 207-212.
29. Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species [J]. Prep Biochem 1972; 2: 139-165.
30. Thompson J, Hu H, Scharff J, Neville Jr DM. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995; 270: 28037-28041.
31. Sun X, Zhang ZR. Preparation of lipid-protamine-DNA complexes and evaluation of their transfection efficiencies in vitro. Yao Xue Xue Bao 2004; 39: 792-796.
32. Wefer J, Harris RA, Lobell A. Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNbeta. J Neuroimmunol 2004; 149: 66-76.
33. Kono DH, Urban JL, Horvath SJ, Ando DG, Saavedra RA, Hood L. Two minor determinants of myelin basic protein induce experimental allergic encephalo-myelitis in SJL/J mice. J Exp Med 1988; 168: 213-227.
34. Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 2000; 110: 195-208.
35. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 11-23.
36. Alheim M, Lazdina U, Milich DR, Sallberg M. Flow cytometric determination of cytokine production and proliferation in hepatitis B core antigen specific murine CD4 cells: Lack of correlation between number of cytokine producing cells and cytokine levels in supernatant. J Immunol Methods 2001; 258: 157-167.
37. Kerttula TO, Collin P, Maki M, Hurme M. Normal T-helper 1/T-helper 2 balance in peripheral blood of coeliac disease patients. Scand J Immunol 1999; 49: 197-202.